

Test to treat in a single patient visit

An easy-to-use workflow with <15 seconds hands-on time



Step 1

Load sample into device port



Step 2

Slide switch to close port



Step 3

Read the results

visby medical™

For more information, call 1-833-468-4729.

The Visby Medical Respiratory Health Test has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection and differentiation of nucleic acid from SARS-CoV-2, influenza A, and influenza B, not for any other viruses or pathogens; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

PL-000221 Rev A

The power of PCR in your hands

Results delivered at the point of care in under 30 minutes



True PCR results in
under 30 minutes



Portable, deployable,
and scalable



PCR
accuracy



Instrument free - no
capital investment, service
contracts, maintenance
or calibration

visby medical™

1-833-GoVisby (1-833-468-4729)

Visit our website at visbymedical.com or scan this QR Code.



Visby Medical Respiratory Health Test

Product Specifications Sheet

Product	Visby Medical Respiratory Health Test			
Orderable Part (Case)	Visby Medical Respiratory Health (2 boxes of 10 devices)			
Orderable SKU Number	SKU: PS-400380 (Case equals two boxes)			
Technology	Reverse Transcription Polymerase Chain Reaction (RT-PCR)			
Targets	<i>Influenza A</i>	<i>Influenza B</i>	<i>SARS-CoV-2</i>	
Target Details	Flu A: Evaluated against a panel of 10 strains of influenza A H1N1 and 10 strains of Influenza A H3N2	Flu B: Evaluated against a panel of 12 strains of influenza B	Visby follows the FDA's Policy for Evaluating Impact of Viral Mutations on COVID-19 Tests by monitoring SARS-CoV-2 sequences for mutations	
Complexity	EUA for use in CLIA-waived point-of-care settings			
Instrument	None needed			
Sample Type	Nasopharyngeal swab or anterior nasal swab (patient or provider collected)			
Results	Qualitative results - visual colorimetric indicator next to the target pathogen			
Device Use	Single use			
Sample Extraction	None needed			
Precision Pipetting	Not required			
Turnaround Time (TAT)	30 minutes			
Internal Control	Process control			
Limit of Detection (LOD)	<i>Influenza A</i>	<i>Influenza B</i>	<i>SARS-CoV-2</i>	
	Influenza A/H1N1 2009, Brisbane/02/18 106 copies/swab Influenza A/H3N2, Kansas/14/2017 125 copies/swab	Influenza B/ Washington/02/19 728 copies / swab Influenza B/ Oklahoma/10/2018 778 copies / swab	SARS-CoV-2 (USA-WA1/2020) 100 copies / swab	
Positive Percent Agreement (PPA)*	96.8%	96.9%	96.1%	
Negative Percent Agreement (NPA)*	99.0%	100%	98.2%	
Swab Stability in Visby Buffer	Up to 120 minutes (2 hours) at room temperature 59°F - 86°F (15°C - 30°C) Up to 48 hours at refrigerated temperature 36°F - 46°F (2°C - 8°C)			
Kit and Device Storage	Temperature: 36°F - 86°F (2°C - 30°C), Humidity: 5% - 80%			
External Controls	Refer to Instructions for Use or Contact Visby Customer Experience Team Email: support@visby.com; Phone: 1-833-GoVisby (1-833-468-4729)			

* Data is a combination of prospective fresh specimens (NP and AN), banked specimens (NP), and surrogate specimens (NP)

Visby Medical Sexual Health Test

Product Specifications Sheet

Product	Visby Medical Sexual Health Test			
Orderable Part (Case)	Visby Medical Sexual Health - 20 devices per case			
Orderable SKU Number	Visby Medical SKU PS-400372: 2 inner boxes of 10 devices			
Technology	PCR			
Targets	<i>Chlamydia trachomatis</i> (CT)	<i>Neisseria gonorrhoeae</i> (NG)	<i>Trichomonas vaginalis</i> (TV)	
Target Details	CT: evaluated against a panel of 16 serovars, including Swedish variant (nvCT)	NG: evaluated against a panel of 32 different strains	TV: evaluated against a panel of 17 different strains	
Complexity	CLIA-Waived			
Instrument	None needed			
Results	Individual qualitative result for Chlamydia, Gonorrhea and Trichomoniasis visually interpreted on the Visby Medical Sexual Health test device			
Sample Extraction	No additional sample extraction required, raw sample added to the device			
Pipetting	Single use pipette supplied in kit			
Turnaround Time (TAT)	Under 30 minutes			
Internal Control	Combination of electronic control and assay process controls			
Limit of Detection (LOD)	CT (Serovar)	NG (Strain)	TV (Strain)	
Patient Collected Vaginal Swab	Serovar H - 16.0 EB/mL Serovar D - 5.9 EB/mL	NG 19424 - 5.7 CFU/mL NG 49226 - 6.2 CFU/mL	TV 30001 - 1.2 troph/mL TV 30238 - 0.24 troph/mL	
Positive Percent Agreement (PPA)	97.4%	97.8%	99.3% Sensitivity	
Negative Percent Agreement (NPA)	97.8%	99.1%	96.7% Specificity	
Swab Stability* <small>*in Visby Sexual Health Buffer</small>	2°-30°C: 4 Hours, <-15°C: 90 days			
Kit and Device Storage	Temperature: 36°F-86°F (2°C-30°C) Humidity: 5%-80%			
Sample Collection Kit	Visby Medical Sexual Health, Vaginal Specimen Collection Kit, 50 Pack			
Sample Collection Kit P/N	SKU: PS-000715			
Power Adapter† <small>†(sold separately)</small>	SKU: PS-000288			
External Controls	Refer to Instructions for Use ZeptoMetrix external controls: NATCTNGTV-POS-IVD, NATCTNGTV-NEG-IVD			